The aim of this study, a retrospective cohort analysis, was to calculate the costs and consequences of exposure to and compliance with drug treatments recommended for refracture prevention in post-menopausal women with hip fracture. All women aged ≥65 years and admitted to hospital with a main or secondary diagnosis of hip fracture in the period 1 January 2006 - 31 December 2008 were included. These patients were classified as exposed /not exposed to a drug treatment for fracture prevention. Adherence to treatment was calculated in the group of patients treated with bisphosphonates. The following items were considered in the cost analysis: drug treatments supplied, diagnostic tests administered and hospital admissions recorded during the observation period. In total, 5,167 patients were included in the analysis, of whom only 33.9% received drug therapy post hip fracture; of those treated with bisphosphonates, only 21.1% were found to have adhered to the treatment. Exposure to drug treatment reduced the risk of refracture by 39.5% and the risk of death by 55.1%. The mean cost increases observed in the patients who, according to indication, were exposed to drug treatment (+ € 256) or submitted to a diagnostic test (+ € 40) were offset by a sizeable reduction in costs of hospitalisation for refracture (- € 703). Drug treatment for the prevention of bone refractures in hip fracture patients was found to be effective in reducing the risk of refracture and death, and cost-effective, reducing overall patient management costs.

Tarantino, U., Ortolani, S., Esposti, L., Veronesi, C., Buda, S., Brandi, M. (2011). Analysis of the costs and consequences of adherence to therapy in hip fracture patients. Results of a longitudinal analysis of administrative databases. CLINICAL CASES IN MINERAL AND BONE METABOLISM, 8(1), 57-62.

Analysis of the costs and consequences of adherence to therapy in hip fracture patients. Results of a longitudinal analysis of administrative databases

TARANTINO, UMBERTO;
2011-01-01

Abstract

The aim of this study, a retrospective cohort analysis, was to calculate the costs and consequences of exposure to and compliance with drug treatments recommended for refracture prevention in post-menopausal women with hip fracture. All women aged ≥65 years and admitted to hospital with a main or secondary diagnosis of hip fracture in the period 1 January 2006 - 31 December 2008 were included. These patients were classified as exposed /not exposed to a drug treatment for fracture prevention. Adherence to treatment was calculated in the group of patients treated with bisphosphonates. The following items were considered in the cost analysis: drug treatments supplied, diagnostic tests administered and hospital admissions recorded during the observation period. In total, 5,167 patients were included in the analysis, of whom only 33.9% received drug therapy post hip fracture; of those treated with bisphosphonates, only 21.1% were found to have adhered to the treatment. Exposure to drug treatment reduced the risk of refracture by 39.5% and the risk of death by 55.1%. The mean cost increases observed in the patients who, according to indication, were exposed to drug treatment (+ € 256) or submitted to a diagnostic test (+ € 40) were offset by a sizeable reduction in costs of hospitalisation for refracture (- € 703). Drug treatment for the prevention of bone refractures in hip fracture patients was found to be effective in reducing the risk of refracture and death, and cost-effective, reducing overall patient management costs.
gen-2011
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/33 - MALATTIE APPARATO LOCOMOTORE
English
Adherence to treatment; Cost of disease; Drug use; Hip fracture; Osteoporosis
Tarantino, U., Ortolani, S., Esposti, L., Veronesi, C., Buda, S., Brandi, M. (2011). Analysis of the costs and consequences of adherence to therapy in hip fracture patients. Results of a longitudinal analysis of administrative databases. CLINICAL CASES IN MINERAL AND BONE METABOLISM, 8(1), 57-62.
Tarantino, U; Ortolani, S; Esposti, L; Veronesi, C; Buda, S; Brandi, M
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/54246
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 9
  • ???jsp.display-item.citation.isi??? ND
social impact